$45m revenue per annum - market cap $7m, page-4

Just going over some numbers...... this looks cheap just on the existing business.....

--------------------------

Forecast for the 09/10 Financial Year NuSep announced its maiden profit for the first six months of the financial year ending 31 December 2010. NuSep confirmed at that time that it is on track to make a profit of $500,000
this financial year from its existing business.
BioInquire has budgeted to make a profit of US$1.2m in the year to 31 March 2011. NuSep has adjusted its profit projection to 30 June 2010 to reflect A$500,000 contribution from the BioInquire business increasing its overall profit to $1m for the year ended 30 June 2010. Below is an overview of the 09/10 financial year forecast.

THE 09/10 REVISED PROFIT FORECAST
NUSEP BIOINQUIRE
(6 MONTHS)
COMBINED
SALES $4M $1.5M $5.5M
GROSS MARGIN $2.56M $1.3M $3.86M
NET PROFIT $0.51M $0.5M $1.01M

The above combined profit translates into a earnings per share increase post the acquisition from
2.1? to 4.1? per share on a fully diluted basis (24.4m shares).